Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christian Hartmann

Showing results (251-260 of 265) with videos related to

Pageof 27
Sort By:
Acta Neuropathologica|April 20, 2021
Glioblastomas with primitive neuronal component harbor a distinct methylation and copy-number profile with inactivation of TP53, PTEN, and RB1Abigail K Suwala, Damian Stichel, Daniel Schrimpf, et al.
Acta Neuropathologica|February 14, 2019
Papillary glioneuronal tumor (PGNT) exhibits a characteristic methylation profile and fusions involving PRKCAYanghao Hou, Jorge Pinheiro, Felix Sahm, et al.
Neuro-Oncology|April 18, 2025
Molecular signatures define BAP1-altered meningioma as a distinct CNS tumor with deregulation of Polycomb repressive complex target genesPhilipp Sievers, Sonali Arora, Thomas Hielscher, et al.
Acta Neuropathologica|June 11, 2025
Outcome-associated factors in a molecularly defined cohort of central neurocytomaMaja Krech, Amos Muench, Daniel Teichmann, et al.
Acta Neuropathologica Communications|October 30, 2019
Tumors diagnosed as cerebellar glioblastoma comprise distinct molecular entitiesAnnekathrin Reinhardt, Damian Stichel, Daniel Schrimpf, et al.
Neuro-Oncology|June 3, 2026
Primary Mismatch Repair Deficient Glioma (PMMRDG), IDH-wildtype and H3-wildtype: A Giant Cell Tumor with Potential for Long-Term Survival Occurring at all AgesAbigail K Suwala, Dennis Friedel, Felix E Hinz, et al.
The Lancet. Oncology|October 1, 2016
Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup studyBrigitta G Baumert, Monika E Hegi, Martin J van den Bent, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 25, 2020
Nonmetastatic Medulloblastoma of Early Childhood: Results From the Prospective Clinical Trial HIT-2000 and An Extended Validation CohortMartin Mynarek, Katja von Hoff, Torsten Pietsch, et al.
Neuro-Oncology|September 30, 2025
Developing an advanced risk stratification model for pediatric intracranial ependymoma based on the prospective trial E-HIT2000 and subsequent registriesKatja von Hoff, Denise Obrecht-Sturm, David R Ghasemi, et al.
Acta Neuropathologica|March 23, 2018
Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, CDKN2A/B and ATRX alterationsAnnekathrin Reinhardt, Damian Stichel, Daniel Schrimpf, et al.
Pageof 27

Showing results (251-260 of 265) with videos related to

Sort By:
Pageof 27
Acta Neuropathologica|April 20, 2021
Glioblastomas with primitive neuronal component harbor a distinct methylation and copy-number profile with inactivation of TP53, PTEN, and RB1Abigail K Suwala, Damian Stichel, Daniel Schrimpf, et al.
Acta Neuropathologica|February 14, 2019
Papillary glioneuronal tumor (PGNT) exhibits a characteristic methylation profile and fusions involving PRKCAYanghao Hou, Jorge Pinheiro, Felix Sahm, et al.
Neuro-Oncology|April 18, 2025
Molecular signatures define BAP1-altered meningioma as a distinct CNS tumor with deregulation of Polycomb repressive complex target genesPhilipp Sievers, Sonali Arora, Thomas Hielscher, et al.
Acta Neuropathologica|June 11, 2025
Outcome-associated factors in a molecularly defined cohort of central neurocytomaMaja Krech, Amos Muench, Daniel Teichmann, et al.
Acta Neuropathologica Communications|October 30, 2019
Tumors diagnosed as cerebellar glioblastoma comprise distinct molecular entitiesAnnekathrin Reinhardt, Damian Stichel, Daniel Schrimpf, et al.
Neuro-Oncology|June 3, 2026
Primary Mismatch Repair Deficient Glioma (PMMRDG), IDH-wildtype and H3-wildtype: A Giant Cell Tumor with Potential for Long-Term Survival Occurring at all AgesAbigail K Suwala, Dennis Friedel, Felix E Hinz, et al.
The Lancet. Oncology|October 1, 2016
Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup studyBrigitta G Baumert, Monika E Hegi, Martin J van den Bent, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 25, 2020
Nonmetastatic Medulloblastoma of Early Childhood: Results From the Prospective Clinical Trial HIT-2000 and An Extended Validation CohortMartin Mynarek, Katja von Hoff, Torsten Pietsch, et al.
Neuro-Oncology|September 30, 2025
Developing an advanced risk stratification model for pediatric intracranial ependymoma based on the prospective trial E-HIT2000 and subsequent registriesKatja von Hoff, Denise Obrecht-Sturm, David R Ghasemi, et al.
Acta Neuropathologica|March 23, 2018
Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, CDKN2A/B and ATRX alterationsAnnekathrin Reinhardt, Damian Stichel, Daniel Schrimpf, et al.
Pageof 27